EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AIM Vaccine Co's enterprise value is HK$10,101 Mil.
AIM Vaccine Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,299 Mil. Therefore, AIM Vaccine Co's EV-to-Revenue for today is 7.78.
The historical rank and industry rank for AIM Vaccine Co's EV-to-Revenue or its related term are showing as below:
HKSE:06660'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6.9 Med: 15.86 Max: 47.02
Current: 7.78
During the past 5 years, the highest EV-to-Revenue of AIM Vaccine Co was 47.02. The lowest was 6.90. And the median was 15.86.
HKSE:06660's EV-to-Revenue is ranked better than 50.67% of 1038
companies
in the Biotechnology industry
Industry Median: 8.145
vs HKSE:06660: 7.78
As of today (2024-05-27), AIM Vaccine Co's stock price is HK$7.43.
AIM Vaccine Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.07. Therefore, AIM Vaccine Co's PS Ratio for today is 6.93.
AIM Vaccine Co EV-to-Revenue Historical Data
The historical data trend for AIM Vaccine Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM Vaccine Co's EV-to-Revenue
For the Biotechnology subindustry, AIM Vaccine Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's EV-to-Revenue falls into.
AIM Vaccine Co's current Enterprise Value is HK$10,101 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,299 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co (HKSE:06660) EV-to-Revenue Explanation
AIM Vaccine Co's share price for today is HK$7.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of AIM Vaccine Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06660 has been successfully added to your